EP1937639 - PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 07.01.2011 Database last updated on 03.09.2024 | Most recent event Tooltip | 15.08.2014 | Change - lapse in a contracting state | published on 17.09.2014 [2014/38] | Applicant(s) | For all designated states Pfizer Products Inc. Eastern Point Road Groton, CT 06340 / US | [N/P] |
Former [2010/09] | For all designated states Pfizer Products Inc. Eastern Point Road Groton, CT 06340 / US | ||
Former [2008/27] | For all designated states Pfizer Products Incorporated Eastern Point Road Groton, CT 06340 / US | Inventor(s) | 01 /
PATTERSON, Brian, Douglas Agouron Pharmaceuticals Inc. A Pfizer Company 10777 Science Center Drive San Diego, CA 92121 / US | 02 /
SAKATA, Sylvie, Kim Agouron Pharmaceuticals Inc. A Pfizer Company 10777 Science Center Drive San Diego, CA 92121 / US | 03 /
NAMBU, Mitchell, David c/o Ambit Biosciences 4215 Sorrento Valley Blvd San Diego, CA 92121 / US | 04 /
PATEL, Leena, Bharat, Kumar Agouron Pharmaceuticals Inc. A Pfizer Company 10614 Science Center Drive San Diego, CA 92121 / US | 05 /
TATLOCK, John, Howard Agouron Pharmaceuticals Inc. A Pfizer Company 10614 Science Center Drive San Diego, CA 92121 / US | [2008/37] |
Former [2008/27] | 01 /
PATTERSON, Brian, Douglas Agouron Pharmaceuticals Inc. A Pfizer Company 10777 Science Center Drive San Diego, CA 92121 / US | ||
02 /
SAKATA, Sylvie, Kim Agouron Pharmaceuticals Inc. A Pfizer Company 10777 Science Center Drive San Diego, CA 92121 / US | |||
03 /
NAMBU, Mitchell, David Agouron Pharmaceuticals Inc. A Pfizer Company 10777 Science Center Drive San Diego, CA 92121 / US | |||
04 /
PATEL, Leena, Bharat, Kumar Agouron Pharmaceuticals Inc. A Pfizer Company 10614 Science Center Drive San Diego, CA 92121 / US | |||
05 /
TATLOCK, John, Howard Agouron Pharmaceuticals Inc. A Pfizer Company 10614 Science Center Drive San Diego, CA 92121 / US | Representative(s) | Lane, Graham Mark Hamilton Pfizer ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR | [N/P] |
Former [2008/27] | Lane, Graham Mark Hamilton Pfizer Limited, European Patent Department Ramsgate Road Sandwich, Kent CT13 9NJ / GB | Application number, filing date | 06795544.3 | 11.09.2006 | [2008/27] | WO2006IB02639 | Priority number, date | US20050720151P | 23.09.2005 Original published format: US 720151 P | US20050723115P | 03.10.2005 Original published format: US 723115 P | US20050725469P | 11.10.2005 Original published format: US 725469 P | US20060762256P | 25.01.2006 Original published format: US 762256 P | US20060821664P | 07.08.2006 Original published format: US 821664 P | [2008/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2007034312 | Date: | 29.03.2007 | Language: | EN | [2007/13] | Type: | A2 Application without search report | No.: | EP1937639 | Date: | 02.07.2008 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.03.2007 takes the place of the publication of the European patent application. | [2008/27] | Type: | B1 Patent specification | No.: | EP1937639 | Date: | 03.03.2010 | Language: | EN | [2010/09] | Search report(s) | International search report - published on: | EP | 23.08.2007 | Classification | IPC: | C07D213/76, A61K31/4406, A61P39/00 | [2008/27] | CPC: |
C07D213/76 (EP,KR,US);
A61K31/166 (KR);
A61K31/4406 (KR);
A61P31/18 (EP);
A61P39/00 (EP);
A61P43/00 (EP);
C07D401/12 (EP,KR,US);
C07D405/12 (EP,KR,US);
C07D413/12 (EP,KR,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/27] | Extension states | AL | 23.04.2008 | BA | 23.04.2008 | HR | 23.04.2008 | MK | 23.04.2008 | RS | 23.04.2008 | Title | German: | PYRIDINAMINOSULFONYLSUBSTITUIERTE BENZAMIDE ALS INHIBITOREN VON CYTOCHROM P450 3A4 (CYP3A4) | [2008/27] | English: | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | [2008/27] | French: | BENZAMIDES A SUBSTITUTION PYRIDINEAMINOSULFONYLE COMME INHIBITEURS DE CYTOCHROME P450 3A4 (CYP3A4) | [2008/27] | Entry into regional phase | 23.04.2008 | National basic fee paid | 23.04.2008 | Designation fee(s) paid | 23.04.2008 | Examination fee paid | Examination procedure | 27.02.2008 | Amendment by applicant (claims and/or description) | 23.04.2008 | Examination requested [2008/27] | 06.11.2009 | Communication of intention to grant the patent | 25.01.2010 | Fee for grant paid | 25.01.2010 | Fee for publishing/printing paid | Opposition(s) | 06.12.2010 | No opposition filed within time limit [2011/06] | Fees paid | Renewal fee | 30.09.2008 | Renewal fee patent year 03 | 30.09.2009 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | MC | 30.09.2010 | [2014/38] |
Former [2011/20] | MC | 30.09.2010 | Cited in | International search | [A]US2003166584 (HU OLIVER YOA-PU [TW], et al) [A] 1-21* paragraph [0016] *; | [A] - DRESSER G K ET AL, "PHARMACOKINETIC-PHARMACODYNAMIC CONSEQUENCES AND CLINICAL RELEVANCEOF CYTOCHROME P450 3A4 INHIBITION", CLINICAL PHARMACOKINETICS, LEA & FEBIGER, PHILADELPHIA, PA, US, (200001), vol. 38, no. 1, pages 41 - 57, XP000952582 [A] 1-21 * table II * * page 50, paragraph 5.2 * DOI: http://dx.doi.org/10.2165/00003088-200038010-00003 |